Genotyping Market Genotyping Market by Technology (Polymerase Chain Reaction, Sequencing, Microarray, Electrophoresis, MALDI_TOF), Application (Pharmacogenomics, Diagnostic Research, Animal Genetics, Agricultural Biotechnology) & by Products - Global Forecast to

Summary The global genotyping market is estimated to grow at a CAGR of 22.3% from 2015 to 2020 to reach $17.0 Billion in Advances in technology, decreasing prices of DNA sequencing, increasing incidence and awareness on genetic diseases & personalized medicine, increasing demand for pharmacogenomics in drug discovery & development, and the increased use of genetic analysis in animal & plant livestock are the major factors driving market growth.global genotyping market Other drivers include the increasing application areas of genotyping, increasing demand for affordable genotyping services, increasing access to healthcare, and growing investments by leading players in emerging markets. However, the lack of well-trained technical personnel and proper reimbursement are some major factors that could hinder the growth of this market to a certain extent. The market studied in this report is mainly segmented by products, technologies, applications, and end users. Based on product, the market is segmented into instruments (sequencers, & analyzers), reagents & kits, and bioinformatics software and services. Reagents & kits market is forecasted to grow at a highest CAGR of 24.9% during the forecast period owing to its increasing demand with increasing applications of genotyping tests. On the basis of application, the market is segmented into pharmacogenomics, diagnostic research, animal genetics, agricultural biotechnology, and others (prenatal testing, parental testing, forensics, and microbial genotyping). The pharmacogenomics segment is expected to grow at a highest CAGR of 23.4% during the forecast period. The high growth in this segment is attributed to increasing use of genotyping in drug development process & to analyze the effects of drug.

Factors such as technological advancements in OIS, rising incidence of cancer cases, increasing number of cases related to recurrence of secondary tumor, rising adoption of OIS, and developing healthcare infrastructure (especially in emerging nations) are driving the growth of the global oncology information system market. However, factors such as shortage of healthcare IT professionals and unfavorable healthcare reforms in the U.S. restrict the growth of this market. As of 2014, North America accounted for the largest share of the global oncology information system market, followed by Europe. However, the Asia-Pacific market is expected to grow at the highest CAGR of 11.5% from 2014 to This high growth can be attributed to huge patient population base, government-sponsored cancer programs, rising trends of medical tourism owing to low-cost treatments, and increasing focus of global market players on developing nations. Some of the major players in the global oncology information system market are Accuray Incorporated (U.S.), Altos Solutions, Inc. (U.S.), Cerner Corporation (U.S.), Elekta AB (Sweden), Epic Systems Corporation (U.S.), Koninklijke Philips N.V. (The Netherlands), McKesson Corporation (U.S.), and Varian Medical Systems, Inc. (U.S.).

The global genotyping market is dominated by North America, followed by Europe. The Asia-Pacific market is expected to witness the highest growth due to the growing healthcare infrastructure, improving healthcare services, increasing investments by major players and governments, and increasing clinical research activities. North America and Europe are expected to grow at a sluggish rate since these are relatively saturated markets. Prominent players in this market are Affymetrix, Inc. (U.S.), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies (U.S.), Beckman Coulter (U.S.), Sequenom, Inc. (U.S.), Roche (Switzerland), GE Healthcare (U.K.), and Fluidigm Corporation (U.S.).

The genotyping market studied in this report is mainly segmented by product, technology, applications, and end user. The market, by product & services, is segmented into instruments (sequencers & amplifiers, and analyzers), reagents and kits, bioinformatics software and services. Reagents & kits market is expected to grow at a CAGR of during the forecast period of 2015 to Based on application, the market is segmented into pharmacogenomics, diagnostic research, animal genetics, agricultural biotechnology, and others (prenatal testing, parental testing, forensics, and microbial genotyping). The pharmacogenomics segment is expected to grow at a highest CAGR of 23.4% during the forecast period. The market, by technology, is segmented into microarray, capillary electrophoresis, polymerase chain reaction (PCR), sequencing, MALDI-TOF, and others (allele specific oligonucleotide (ASO) probes, & in situ hybridization). Sequencing is the high growth market, owing to its widening application areas of DNA sequencing technologies, technological advancements, and the availability of high-speed sequencing instruments are expected to contribute to the growth of the DNA sequencing market in the coming years.genotyping market Developed geographies like North America and Europe are saturated markets and expected to grow at a slower rate, whereas the Asian market is expected to witness the highest growth of CAGR, 25.4% from 2015 to 2020, due to the huge demand for better healthcare services, expanding per capita income, increasing ongoing clinical trials in these regions, and the increasing focus of leading players on these regions. The key players operating in genotyping market are Affymetrix, Inc. (U.S.), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies (U.S.), Beckman Coulter (U.S.), Sequenom, Inc. (U.S.), Roche (Switzerland), GE Healthcare (U.K.), and Fluidigm Corporation (U.S.).

About MarketsandMarkets MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Contact: Mr. Rohan North - Dominion Plaza, 17304,Preston Road, Suite 800, Dallas, TX Tel: